Logo image of ELDN

ELEDON PHARMACEUTICALS INC (ELDN) Stock Fundamental Analysis

NASDAQ:ELDN - Nasdaq - US28617K1016 - Common Stock - Currency: USD

3.24  -0.12 (-3.57%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ELDN. ELDN was compared to 568 industry peers in the Biotechnology industry. While ELDN has a great health rating, there are worries on its profitability. ELDN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ELDN had negative earnings in the past year.
ELDN had a negative operating cash flow in the past year.
In the past 5 years ELDN always reported negative net income.
ELDN had a negative operating cash flow in each of the past 5 years.
ELDN Yearly Net Income VS EBIT VS OCF VS FCFELDN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a decent Return On Assets value of -33.72%, ELDN is doing good in the industry, outperforming 62.85% of the companies in the same industry.
ELDN's Return On Equity of -50.63% is fine compared to the rest of the industry. ELDN outperforms 64.79% of its industry peers.
Industry RankSector Rank
ROA -33.72%
ROE -50.63%
ROIC N/A
ROA(3y)-82.01%
ROA(5y)-55.57%
ROE(3y)-91.6%
ROE(5y)-61.56%
ROIC(3y)N/A
ROIC(5y)N/A
ELDN Yearly ROA, ROE, ROICELDN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ELDN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELDN Yearly Profit, Operating, Gross MarginsELDN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, ELDN has more shares outstanding
Compared to 5 years ago, ELDN has more shares outstanding
ELDN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ELDN Yearly Shares OutstandingELDN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ELDN Yearly Total Debt VS Total AssetsELDN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

ELDN has an Altman-Z score of -1.39. This is a bad value and indicates that ELDN is not financially healthy and even has some risk of bankruptcy.
ELDN has a Altman-Z score (-1.39) which is in line with its industry peers.
There is no outstanding debt for ELDN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.39
ROIC/WACCN/A
WACCN/A
ELDN Yearly LT Debt VS Equity VS FCFELDN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 12.42 indicates that ELDN has no problem at all paying its short term obligations.
ELDN has a better Current ratio (12.42) than 85.04% of its industry peers.
A Quick Ratio of 12.42 indicates that ELDN has no problem at all paying its short term obligations.
ELDN has a Quick ratio of 12.42. This is amongst the best in the industry. ELDN outperforms 85.04% of its industry peers.
Industry RankSector Rank
Current Ratio 12.42
Quick Ratio 12.42
ELDN Yearly Current Assets VS Current LiabilitesELDN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.34% over the past year.
EPS 1Y (TTM)41.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%331.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ELDN will show a small growth in Earnings Per Share. The EPS will grow by 4.68% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-15.36%
EPS Next 2Y-6.91%
EPS Next 3Y-6.97%
EPS Next 5Y4.68%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELDN Yearly Revenue VS EstimatesELDN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
ELDN Yearly EPS VS EstimatesELDN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 -100 -200 -300 -400 -500

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ELDN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELDN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELDN Price Earnings VS Forward Price EarningsELDN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELDN Per share dataELDN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A cheap valuation may be justified as ELDN's earnings are expected to decrease with -6.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.91%
EPS Next 3Y-6.97%

More info and screens

0

5. Dividend

5.1 Amount

ELDN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELEDON PHARMACEUTICALS INC

NASDAQ:ELDN (4/25/2025, 8:03:16 PM)

3.24

-0.12 (-3.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-20 2025-03-20/amc
Earnings (Next)05-08 2025-05-08
Inst Owners59.15%
Inst Owner Change0.04%
Ins Owners0.03%
Ins Owner Change0%
Market Cap194.01M
Analysts85
Price Target10.61 (227.47%)
Short Float %2.37%
Short Ratio6.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)153.48%
Min EPS beat(2)0.4%
Max EPS beat(2)306.56%
EPS beat(4)3
Avg EPS beat(4)18.31%
Min EPS beat(4)-242.52%
Max EPS beat(4)306.56%
EPS beat(8)6
Avg EPS beat(8)14.75%
EPS beat(12)9
Avg EPS beat(12)10.49%
EPS beat(16)11
Avg EPS beat(16)5.47%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16.8%
EPS NQ rev (1m)-19.74%
EPS NQ rev (3m)-1.11%
EPS NY rev (1m)-8.7%
EPS NY rev (3m)-16.71%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.64
P/tB 2.26
EV/EBITDA N/A
EPS(TTM)-1.05
EYN/A
EPS(NY)-1.21
Fwd EYN/A
FCF(TTM)-0.79
FCFYN/A
OCF(TTM)-0.79
OCFYN/A
SpS0
BVpS1.97
TBVpS1.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.72%
ROE -50.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-82.01%
ROA(5y)-55.57%
ROE(3y)-91.6%
ROE(5y)-61.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.42
Quick Ratio 12.42
Altman-Z -1.39
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%331.03%
EPS Next Y-15.36%
EPS Next 2Y-6.91%
EPS Next 3Y-6.97%
EPS Next 5Y4.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-89.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.59%
OCF growth 3YN/A
OCF growth 5YN/A